Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopamine neurons in the substantia nigra pars compacta. To date, although a bulk of evidences suggest that the etiology of PD is multifactorial, none of the mechanisms yet proposed have been considered conclusive. Activated glia seem to play a critical role in the degeneration of nigral dopaminergic neurons in PD, by secreting a complex array of cytokines, chemokines, proteolytic enzymes, reactive oxygen/nitrogen species and complement proteins that may have deleterious effects on the dopaminergic system. Recently, it has been reported that microglia activation and immunity are key factors contributing to disease progression. Here, we review studies on the role of inflammation mediated by the innate and adaptive immune systems involved in the pathogenesis of PD and highlight some of the important areas for future investigation.
Keywords: Parkinson's disease, microglia, inflammation, immune system, dopamine neurons, cytokines, chemokines, proteolytic enzymes, Oxidative stress, pesticides
Current Pharmaceutical Design
Title: Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Volume: 18 Issue: 2
Author(s): Maria Antonietta Panaro and Antonia Cianciulli
Affiliation:
Keywords: Parkinson's disease, microglia, inflammation, immune system, dopamine neurons, cytokines, chemokines, proteolytic enzymes, Oxidative stress, pesticides
Abstract: Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopamine neurons in the substantia nigra pars compacta. To date, although a bulk of evidences suggest that the etiology of PD is multifactorial, none of the mechanisms yet proposed have been considered conclusive. Activated glia seem to play a critical role in the degeneration of nigral dopaminergic neurons in PD, by secreting a complex array of cytokines, chemokines, proteolytic enzymes, reactive oxygen/nitrogen species and complement proteins that may have deleterious effects on the dopaminergic system. Recently, it has been reported that microglia activation and immunity are key factors contributing to disease progression. Here, we review studies on the role of inflammation mediated by the innate and adaptive immune systems involved in the pathogenesis of PD and highlight some of the important areas for future investigation.
Export Options
About this article
Cite this article as:
Antonietta Panaro Maria and Cianciulli Antonia, Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease, Current Pharmaceutical Design 2012; 18 (2) . https://dx.doi.org/10.2174/138161212799040574
DOI https://dx.doi.org/10.2174/138161212799040574 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times
Current Neuropharmacology Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design Neurokinin Peptides and Neurokinin Receptors as Potential Therapeutic Intervention Targets of Basal Ganglia in the Prevention and Treatment of Parkinsons Disease
Current Drug Targets In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Current Therapy of Drugs in Amyotrophic Lateral Sclerosis
Current Neuropharmacology Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science Red Cell Glycolytic Enzyme Disorders Caused by Mutations: An Update
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot topic: Role of Inflammation in Neurological and Psychiatric Disorders (Guest Editor: Mohtashem Samsam)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Glycans and Glycan-Binding Proteins in Brain: Galectin-1-Induced Expression of Neurotrophic Factors in Astrocytes
Current Drug Targets Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins
Current Organic Chemistry Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry Establishment of a Secondary Screening Assay for P/Q-Type Calcium Channel Blockers
Combinatorial Chemistry & High Throughput Screening Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Current Neuropharmacology Subject Index to Volume 4
Current Medicinal Chemistry - Central Nervous System Agents Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets